Estrone (E1): Evidence-Based Ways to Improve Your Levels

What Is Estrone (E1) and Why Does It Matter?

Estrone is one of three naturally occurring estrogens in the human body, alongside estradiol (E2) and estriol (E3). Before menopause, estradiol runs the show. After menopause, E1 takes over as the primary circulating estrogen because ovarian estradiol production drops by roughly 90% [1]. That shift makes E1 the default biomarker for estrogen status in postmenopausal women and a clinically relevant number for anyone whose provider suspects estrogen-related pathology.

The body produces postmenopausal E1 mainly through aromatase-driven conversion of androstenedione in adipose tissue [2]. This means your body composition directly shapes your E1 level. Adipose tissue is not passive storage; it functions as an endocrine organ. A 2012 analysis in the Journal of Clinical Endocrinology & Metabolism demonstrated that each 5 kg/m² increase in BMI was associated with a 19% increase in circulating estrone among postmenopausal women [3]. The Endocrine Society's 2017 clinical practice guideline on menopause management identifies E1 measurement as useful "when clinical suspicion of estrogen excess or deficiency exists but E2 levels are inconclusive" [4].

E1 also matters in men. Male patients on testosterone replacement therapy (TRT) sometimes show elevated E1 as a downstream product of peripheral aromatization, especially when body fat percentage is high [5]. Monitoring E1 alongside estradiol gives a fuller picture of total estrogen burden.

Normal Estrone (E1) Ranges by Age and Sex

Reference ranges vary by laboratory, but the most commonly cited values from Mayo Clinic Laboratories and Quest Diagnostics fall within consistent bands. Context determines interpretation.

Premenopausal women show E1 levels between 17 and 200 pg/mL, with the widest fluctuations during the follicular-to-luteal transition [6]. Mid-cycle peaks can reach 150 to 200 pg/mL. Postmenopausal women not receiving hormone therapy typically register 7 to 40 pg/mL [6]. Adult men carry E1 levels between 10 and 60 pg/mL under normal conditions [7].

A single number outside these ranges does not automatically signal pathology. The Endocrine Society recommends interpreting estrone in the context of estradiol, sex hormone-binding globulin (SHBG), and clinical symptoms rather than treating the lab value in isolation [4]. A postmenopausal woman at 45 pg/mL with no symptoms and normal mammography findings may need nothing more than a recheck in six months. A postmenopausal woman at the same level with new-onset vaginal bleeding warrants immediate workup.

The estrone-to-estradiol (E1:E2) ratio also carries clinical weight. A ratio above 1.0 is expected after menopause. Premenopausal ratios well above 1.0 may suggest impaired ovarian function or excessive peripheral aromatization [8].

Evidence-Based Ways to Lower Estrone (E1)

Lowering E1 is typically the goal when excess estrogen drives clinical risk, most commonly in the setting of estrogen-receptor-positive breast cancer, endometrial hyperplasia, or symptomatic estrogen dominance.

Reduce Body Fat

Because adipose tissue is the primary E1 factory after menopause, fat loss is the most direct non-pharmacologic intervention. The Women's Health Initiative Dietary Modification Trial found that postmenopausal women who lost at least 5% of baseline body weight experienced a 15 to 20% reduction in serum estrone over the study period [9]. That trial followed 48,835 women over a median of 8.1 years.

Resistance training compounds the effect. A 2015 randomized controlled trial in Cancer Epidemiology, Biomarkers & Prevention showed that 12 months of combined aerobic and resistance exercise reduced estrone by 5.5% in overweight postmenopausal women, with greater reductions in those who lost the most body fat [10]. The mechanism is straightforward: fewer adipocytes means less aromatase enzyme, which means less conversion of androstenedione to estrone.

Aromatase Inhibitors

For breast cancer patients, aromatase inhibitors (AIs) are the standard pharmacologic approach. These drugs block the aromatase enzyme directly.

Third-generation AIs dominate current practice. Letrozole 2.5 mg daily reduced plasma estrone by 84% in the ATAC trial's pharmacokinetic substudies [11]. Anastrozole 1 mg daily produced comparable suppression at approximately 81% [11]. Exemestane, a steroidal AI dosed at 25 mg daily, achieved 68 to 72% E1 reduction in the IES trial cohort [12].

Dr. Angela Brodie, whose laboratory work at the University of Maryland laid the groundwork for third-generation AIs, noted: "The key advantage of these agents is near-complete suppression of peripheral estrogen synthesis without affecting adrenal steroidogenesis" [13].

AIs are prescription medications with bone-density implications. The ATAC trial reported a 7.2% incidence of fractures in the anastrozole arm versus 4.4% with tamoxifen over five years [11]. Bone mineral density monitoring is standard practice during AI therapy.

Dietary and Lifestyle Modifiers

Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, kale) contain indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM), which shift estrogen metabolism toward the less proliferative 2-hydroxyestrone pathway. A randomized trial published in the Journal of the National Cancer Institute found that 400 mg/day of I3C shifted the urinary 2:16α-hydroxyestrone ratio favorably within 12 weeks [14]. The direct effect on serum E1 levels was modest (approximately 5 to 8% reduction), but the metabolic shift may carry independent cancer-protective significance.

Alcohol restriction also matters. The Nurses' Health Study demonstrated that women consuming two or more alcoholic drinks per day had 20 to 30% higher circulating estrone compared to non-drinkers [15]. Ethanol increases aromatase activity and reduces hepatic estrogen clearance simultaneously.

Fiber intake above 25 grams per day supports fecal estrogen excretion by interrupting enterohepatic recirculation [16]. Soluble fiber binds conjugated estrogens in the gut lumen, preventing reabsorption.

Evidence-Based Ways to Raise Estrone (E1)

Low E1 is the concern when estrogen deficiency produces clinical consequences: vasomotor symptoms, bone loss, urogenital atrophy, or adverse metabolic shifts. The primary population affected is postmenopausal women with symptomatic hypoestrogenism.

Menopausal Hormone Therapy (MHT)

Oral estrogen therapy raises E1 disproportionately because of first-pass hepatic metabolism. Conjugated equine estrogens (CEE) 0.625 mg daily, the formulation used in the Women's Health Initiative (WHI), increased serum E1 by approximately 150 to 200% from baseline in the WHI hormone trials [17]. This first-pass effect is pharmacologically significant: oral estrogens produce a higher E1:E2 ratio than transdermal formulations.

Transdermal estradiol (patches delivering 0.05 mg/day) raises E1 more modestly, typically by 30 to 50%, because it bypasses hepatic first-pass metabolism [18]. The 2022 Menopause Society (formerly NAMS) position statement notes: "Transdermal estradiol is preferred when the clinical goal is to minimize hepatic effects, including E1 elevation, coagulation factor changes, and triglyceride increases" [19].

The choice between oral and transdermal delivery should reflect the clinical goal. If E1 is the specific lab value a provider is trying to raise (uncommon in isolation), oral formulations accomplish this more effectively. If the goal is symptom relief with minimal hepatic impact, transdermal estradiol is the better route.

Phytoestrogens

Soy isoflavones (genistein and daidzein) bind estrogen receptors weakly and may provide modest estrogenic activity. A meta-analysis of 47 trials published in the British Journal of Pharmacology reported that soy isoflavone supplementation at 40 to 80 mg/day produced a small but statistically significant increase in circulating estrone (mean increase 4.1 pg/mL, 95% CI 1.2 to 7.0) [20]. The clinical relevance of this magnitude of change is debatable, but the signal is consistent.

Red clover isoflavones have shown similar weak estrogenic effects. These compounds are not a substitute for prescription hormone therapy in women with significant estrogen-deficiency symptoms.

Body Composition (the Other Direction)

Gaining adipose tissue increases E1 production. This is not a recommendation but a physiologic fact. In severely underweight women (BMI <18.5) with functional hypothalamic amenorrhea, restoring body weight to a healthy range (BMI 20 to 24) reliably increases all three endogenous estrogens, including E1 [21]. The American Society for Reproductive Medicine (ASRM) guideline on functional hypothalamic amenorrhea identifies weight restoration as first-line therapy [22].

The Estrone-to-Estradiol Ratio: What Clinicians Watch

The E1:E2 ratio adds interpretive nuance beyond absolute E1 values. In premenopausal women, a normal E1:E2 ratio ranges from 0.5 to 1.0. After menopause, the ratio climbs above 1.0, often reaching 3:1 or higher, because E2 production drops faster than E1 [8].

An abnormally high E1:E2 ratio in a premenopausal woman may indicate polycystic ovary syndrome (PCOS), obesity-driven peripheral aromatization, or declining ovarian reserve [8]. The ratio is not diagnostic by itself, but it adds a data point that informs the clinical picture.

In men receiving TRT, a disproportionately elevated E1 relative to E2 can signal excessive adipose aromatization. The American Urological Association (AUA) guideline on testosterone therapy recommends monitoring estradiol rather than estrone in most male patients, but some clinicians track both when body fat percentage exceeds 30% [5].

Supplements and Nutraceuticals: What the Evidence Actually Shows

Several supplements are marketed for "estrogen balance," but the evidence base is thin for most of them.

DIM (diindolylmethane) at 100 to 200 mg/day has the strongest data, primarily for shifting estrogen metabolite ratios rather than lowering absolute E1 [14]. It is reasonable as an adjunct in women concerned about estrogen metabolism but should not replace pharmacologic therapy when clinical risk is high.

Calcium D-glucarate is proposed to inhibit beta-glucuronidase, the enzyme that deconjugates estrogen in the gut and permits reabsorption. Animal data supports the mechanism, but human clinical trials are limited to a single small study (N=15) showing modest changes in glucuronidation markers without measured effects on serum estrone [23]. Promising mechanism. Insufficient evidence to recommend.

Sulforaphane, derived from broccoli sprouts, upregulates phase II detoxification enzymes in the liver. A Johns Hopkins trial showed increased urinary excretion of estrogen metabolites with sulforaphane supplementation, but serum E1 was not a primary endpoint [24].

Omega-3 fatty acids at 2 to 4 grams/day have anti-inflammatory properties that may modulate aromatase expression in adipose tissue. A 2014 randomized trial in Cancer Prevention Research found that omega-3 supplementation reduced breast tissue estrone levels by 11% in obese postmenopausal women, though serum E1 changes did not reach significance [25].

When to Retest and What to Track

After initiating any intervention targeting E1, repeat testing at 8 to 12 weeks provides the clearest signal. Aromatase inhibitors produce near-maximal E1 suppression within 2 to 4 weeks, but lifestyle modifications (weight loss, dietary changes) take 8 to 16 weeks to show measurable serum changes [10].

Request the test as a morning fasting draw for consistency. E1 shows less diurnal variation than cortisol, but standardizing collection conditions reduces noise between serial measurements. The Endocrine Society recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the gold-standard assay for estrone measurement, noting that immunoassays "may overestimate E1 concentrations by 20 to 40% due to cross-reactivity with estrogen metabolites" [4].

Track E1 alongside E2, SHBG, and testosterone for a complete hormonal picture. A falling E1 with stable E2 may simply reflect improved estrogen metabolism. A falling E1 with falling E2 suggests global estrogen depletion, which carries different clinical implications and may require intervention to protect bone density and cardiovascular health. Repeat DEXA screening every 1 to 2 years for any patient on prolonged AI therapy or with persistently low E1 values below 10 pg/mL [11].